Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 12/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7230677 | 0.86 | HCAR3 (0.59) | HCAR3ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL2251103 | 0.86 | KMT2A (0.61) | HCAR3ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL989785 | 0.84 | CES2 (0.58) | HCAR3MAPTNPC1PKMKMT2A | |
| SCHEMBL1496463 | 0.84 | HTT (0.67) | HCAR3ALDH1A1MAPTSMN1; SMN2PKM | |
| SCHEMBL10249376 | 0.80 | KAT2B (0.61) | HCAR3ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL11267808 | 0.80 | HCAR3 (0.81) | HCAR3ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL31327382 | 0.80 | LMNA (0.64) | HCAR3ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL973813 | 0.79 | HCAR3 (0.77) | HCAR3ALDH1A1MAPTHTTKMT2A | |
| SCHEMBL9822953 | 0.78 | KMT2A (0.59) | HCAR3ALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL18477376 | 0.78 | MAPT (0.50) | HCAR3ALDH1A1MAPTRAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232272-B2 | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232272-B2 | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232272-B2 | Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-07-31 | — | — | US | disclosed |
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-11 | — | — | US | disclosed |
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-11 | — | — | US | disclosed |
| EP-2229385-A2 | BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Merck Patent GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009062576-A2 | BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062576-A2 | BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | MERCK PATENT GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| EP-2058308-A1 | Benzimidazoledihydrothiadiazinone derivatives used as fructose-1,6-biphosphatase inhibitors and pharmaceutical compositions containing same. | Merck Sante (FR) | 2009-05-13 | — | — | EP | disclosed |
| EP-2058308-A1 | Benzimidazoledihydrothiadiazinone derivatives used as fructose-1,6-biphosphatase inhibitors and pharmaceutical compositions containing same. | Merck Sante (FR) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286129-A1 | NOVEL BENZIMIDAZOLEDIHYDROTHIADIAZINONE DERIVATIVES AS FRUCTOSE-1,6-BISPHOSPHATASE INHIBITORS, AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | FBP1, ALDOA, GCK | HCAR3 3406/4885ALDH1A1 234/4885MAPT 2599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.